# Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

> **NCT04004416** · PHASE4 · COMPLETED · sponsor: **University of Michigan** · enrollment: 143 (actual)

## Conditions studied

- Schizophrenia
- Bipolar Disorder
- Healthy
- Psychosis
- Schizophreniform Disorders
- Schizo Affective Disorder
- Major Depression With Psychotic Features

## Interventions

- **OTHER:** Placebo and fMRI
- **DRUG:** Lorazepam and fMRI

## Key facts

- **NCT ID:** NCT04004416
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004416, "Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04004416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*